Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We'll see. The company has completed every step they said they would thus far. There are negotiations happening as we speak. News is imminent and it will surprise even the company's harshest critics.
Good for you! Best of luck!
Dude, the preaching of scare and fear tactics has been going on here for over 2 years. The company is moving forward at an accelerated pace to complete its stated business plan, and has accomplished everything thus far it has said it would. Screaming and howling at the moon won't change that!
You are assuming numbers that you have no way of knowing will happen. Financing operations for the completion of the expansion will require funding that is only known by the company, not a poster on a message board. Partnership negotiations may be going on as we speak, and sales increases both domestic and foreign are now looming big in the near and far term.
That's great news! It proves SNDY is continuing to aggressively pursue and to finance its stated business plans. Thanks for keeping up with SNDY's expansion plans! Canadian and European expansion is happening as we speak.
Not from these price levels. It took SNDY five years to finally position the company so they could successfully accomplish what was necessary to complete its business plan of attaining the CE Certifications and completing the filings necessary to start its expansion plans for Canada and then Europe. With the hardest obstacles now behind them, they should be able to aggressively pursue their business plans going forward.
Those who bought in at .0005 and .0006 are in a solid position, and it has nothing to do with they "thought something else would happen yesterday." The company is step by step completing and moving forward with their stated business plans of expansion to Canada and Europe. This is not about buying the stock one day and expecting the next day to sell for a big profit. That is strictly a flippers mentality. This is about seeing that the company is moving forward with their business plans and completing each step needed to accomplish their goals.
The R/S scare tactic is now tired and worn out. It has been over 2 years since the first " there will be a R/S in six months" was posted here, and each time six months pass another threat of "there will be a R/S in six monte" is trotted out. The expected periodic dilution is part of paying for the aggressive expansion, and the company is no where close to maxing out it's 2.9 billion share A/S with less than 1.7 billion used to date. Statements made here that they are diluting every week are not valid because that is not what is happening. The last dilution was reported on September 3rd on this board. That was over 2 weeks ago.
The PR followed up on the Presidents letter and reported that the company had filed with Canada. Peeps here were attacking the company because they delayed the filing. They delayed the filing to evaluate the "several options" the company had for expanding to Canada. Now that they followed through on the filing as they said they would, they are being attacked for that! Every step needed is being accomplished one by one. Sales in Canada is next along with European expansion and reporting increased revenues.
Not unless something truly extraordinary happens.
Thanks for your opinion. The company is moving forward. Stay tuned. Canadian licensing a huge step forward for the company and opens up the path to an accelerated European expansion. With Canadian and European expansion achieved due to CE Certification and FDA approved products, SNDY could be acquired by a much larger company.
Boston says - Canadian licensing a huge step forward for the company and opens up the path to an accelerated European expansion. With Canadian and European expansion achieved due to CE Certification and FDA approved products, SNDY will be acquired by a much larger company. Negotiations may already be in progress. All in my opinion of course.
Glad you disagree with my opinion. Good luck!
Glad you agree with my opinion. Good luck!
The PR today is just the first step in the SNDY Canadian expansion plans. Note that in the most recent Presidents letter, SNDY's CEO stated that the company had delayed this filing because they were looking at the multiple options the company had for expanding to Canada before they filed for the Canadian Medical Device License. What we don't know yet, is what that best option is that led to the filing. The next News just might address that option and it could very well be a Canadian Partnership. Europe is next, and those plans will be made public in the near future. Look for the next quarterly report will show substantial increases in sales.
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
All in my opinion of course!
Solos Endoscopy Files for Medical Device License to Distribute its Endoscopic Instruments in Canada
BOSTON, MA, United States, via ETELIGIS INC., 09/16/2014 - - Solos Endoscopy, Inc. (OTC PINK: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has completed its filing for the Canadian Medical Device License, which will allow Solos to sell certain endoscopic instruments, including the MammoView® devices, in Canada.
The Canadian Medical Device License (MDL) is required for manufacturers of Class II, III, and IV medical devices in Canada. Canada's MDL is comparable to the US FDA 510(k) process, except the process of securing an MDL is usually faster for Class II devices, about the same for Class III devices and more complicated for Class IV devices. Health Canada’s Medical Device Bureau (MDB) had previously completed an initial evaluation of certain Solos Endoscopy instruments and has classified its devices as Class II medical devices.
When applying for a Canadian Medical Device License, you will also need to prove that you have a certified ISO 13485:2003 quality system as well as meet the specific requirements of the Canadian Medical Device Regulations (CMDR). Solos Endoscopy Instruments meet all the requirements as the company’s instruments are both FDA and ISO certified.
Solos Endoscopy recently received its ISO 13485:2003 Certification from TUV SUD America. The Certification to ISO 13485:2003 allows Solos Endoscopy to place the CE Mark on the majority of its endoscopic instruments including the MammoView® devices. Upon approval of the application for its Medical Device Registration in Canada, Solos Endoscopy will have the ability to offer its instruments to the multi-billion dollar Canadian market.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The Certification comes at the conclusion of a lengthy Audit with TUV SUD America this past Year. The Audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).
Solos Endoscopy has posted its Certificate from TUV America on its website; (http://www.solosendoscopy.com/pdf/solos-iso-certification.pdf).
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27796
.
Boston says this is just the first in a series of PR's coming out for SNDY!
We'll see. Could go either way. I tend to think that after attaining the CE Certification, and starting the Canadian process, they wouldn't just suddenly close up shop and throw it all away.
Maybe, maybe not. It's all about timing on the stinky pinkies. If you lose, you move on to the next play. Sitting around constantly complaining about it does not and will not change a thing. The company certainly doesn't read this board or give a hoot what is posted here either positive or negative. They are just moving along at their own pace, trying to complete their long range business plans. No one venting or attacking them, or singing praises about them in cyberspace is going to make them do anything differently.
Like I said, it is a dice game just like all stinky pinkies. You roll the dice and if you lose you should have already known beforehand that you could lose everything. If you score a profit, more the better. However the odds are always stacked against you on the unregulated pinkies. It's all pure gambling and there are plenty of peeps with gambling problems playing pinkies.
Just remember that the company does not now, nor have they ever cared about or endorsed anything about what their "critics" or "supporters" have to say in any forum on the net. The company even specifically mentions it in some of their filings. (do the research yourself, the statements are there if you look for them.)
They took years to finally get that CE Certification they needed, but they finally got it. This pinky has a CEO who releases News when he has it, not when shareholders scream at him to release News. He doesn't care about "Investor Relations," or what shareholders have to say, which is not uncommon on the pink sheets, he cares about slowly but surely accomplishing his goals, and takes as long as it takes. That makes this an extremely risky calculated dice game for shareholders.
The CEO has never been in a hurry, and even though that launches massive criticism from shareholders because of constant delays, he really doesn't change his plans. That once again, makes this a huge gamble for shareholders who should know by now that they are rolling the dice with their investment. He takes his time and he dilutes to pay for his expansion plans, and his expansion plans are now finally on the verge of becoming what the company has said they would be, which is Canadian and European sales expansion as well as increased U.S. sales and a possible partnership agreement.
All IMO of course.
Vastly increased Revenues for the quarter ending September 30th will be just part of the imminent News cycle starting SOON! The company has been purposely quiet while other negotiations are going on regarding options in both Canada and Europe.
All in my opinion of course!
Yes indeed, I agree! News is imminent and will SOON be released!
Not quite sure of what you are talking about, or what it has to do with "your opinion."
Boston says: News imminent. SNDY sales have increased x 3 with 15 new hospitals on board and component shipment problems solved. All IMO of course.
That is alway the bottom line for sure. It remains to be seen if SNDY can pull off a reversal.
Huh? Wishing and hoping for no more price increases won't stop them. News trumps gloom and doom.
News trumps predictions of doom and gloom. SNDY News coming soon to the public marketplace in the pinky neighborhood.
All in my opinion, of course :)
The Company has delayed the filing of its application while management has been evaluating its multiple options for the Canadian market. The Company is currently working
with Spectrum Medical Market Consultants to act as its representative in
Canada for its endoscopic instruments including the MammoView® devices.
Solos Endoscopy experienced significant back orders during the first six months
of 2014 due to supply issues related to a component manufacturer. As a result of
the back orders, the Company’s cash flow and sales declined. We are pleased
to inform the shareholders that we have resolved the issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
This is still the stinky pinkies. News drives the pinks not low share prices.
Like I said, the R/S scare tactic being used here has been beaten to death every day for an entire year. It didn't happen and has now become a tired and boring tactic that was worn out months ago. The company is expanding its operations and there are costs involved for an aggressive expansion on both the Canadian and European marketplaces. With 15 new hospitals in the U.S. now being equipped with Solos instruments, and component supply problems resolved, sales should see a significant increase as stated in the most recent Officer/Director disclosure dated July 18th.
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
.
Like I said, the R/S scare tactic being used here has been beaten to death every day for an entire year. It didn't happen and has now become a tired and boring tactic that was worn out months ago. The company is expanding its operations and there are costs involved for an aggressive expansion on both the Canadian and European marketplaces. With 15 new hospitals in the U.S. now being equipped with Solos instruments, and component supply problems resolved, sales should see a significant increase as stated in the most recent Officer/Director disclosure dated July 18th.
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
.
It is now going on about a year that the R/S scare has been selectively and tactically touted day after day, month after month, as supposedly happening at any moment here. It hasn't happened and it's pretty much just worn out rhetoric at this point. There are still over a Billion shares that would have to be burned through to max out the A/S of 2.9 billion. Not anywhere near that point now, and all the constant, repetitive, daily, non stop R/S talk won't change the fact that it hasn't happened and is still a long way from happening, if it ever happens. The company is setting up to become profitable and has almost zero debt. The only reversal happening here will be a reversal in the direction of the share price after the company breaks it's calculated silence and starts its next News cycle.
Be alert for News. There has been a lot of activity behind the scenes as the company has been making important expansion decisions and is getting ready to release news. All IMO of course.
Really? Are you saying they didn't get the much valued CE Certification they said they would get and worked so hard and so long on getting? They have the credentials posted on their website and their products were approved to sell in Canada.
Sales this quarter will be up by at least 200%. The 15 new hospitals now using Solos equipment, and the components held up by the manufacturer that caused backorders and slowed equipment sales previously are now back in line are positively impacting sales in the U.S.A., and will be in Canada as well. The company is building inventory and negotiating the best of multiple options for the Canadian expansion. Europe will also be in play. All IMO of course.
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
.
Yes, that's old news. Everyone who read the July 18th Presidents letter, including you, already knew that. The company has several options for its expansion move to Canada. They are IMO, building inventory and negotiating their best options.
Solos Endoscopy experienced significant back orders during the first six months
of 2014 due to supply issues related to a component manufacturer. As a result of
the back orders, the Company’s cash flow and sales declined. We are pleased
to inform the shareholders that we have resolved the issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.
You need to go back and read the most recent Presidents Letter to Shareholders from July 18, 2014. The delay is explained in the letter.
The Company has
delayed the filing of its application while management has been evaluating its
multiple options for the Canadian market. The Company is currently working
with Spectrum Medical Market Consultants to act as its representative in
Canada for its endoscopic instruments including the MammoView® devices
That's not unusual for the stinky pinkies! Most of the time, nothing happens the way shareholders think they will happen or when they will happen. It's all speculation.
You keep asking, but I'm sure you realize that only the company knows the answer to that question. The sooner the better of course!